Positron Corporation Funds Research for Niagara University's Academic Center For Integrated Sciences.

HOUSTON -- Positron Corporation (OTCBB:POSC) (the "Company"), a developer and manufacturer of Positron Emission Tomography (PET) medical devices, announced that it has agreed to fund Niagara University's Academic Center for Integrated Sciences. The funding is to be used exclusively to support Niagara University undergraduate Biology and Chemistry students for research work on a collaborative medico-informatics project with the Academic Center.

The research initiative will be conducted at the Heart Center of Niagara and evaluate the prognostic and diagnostic utility of PET to guide and monitor coronary disease reversal and prevention therapy. Patients who have had more than one PET study and have had their pre-test disease risk assessed by Cadenza software are included in the retrospective analysis. The resulting data will be submitted for publication in select peer reviewed medical journals.

Joseph Oliverio, President of Positron stated, "There is an emerging trend in medicine where patients are able to choose medical management vs. surgical treatment of coronary disease. The research being performed in Niagara will not only attempt to demonstrate the ability to reverse disease non-surgically but more importantly introduce cardiac PET as the preferred imaging modality by cardiologists to guide therapy setting the stage for a new imaging center model."

About Positron:

Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM(TM) systems are in use at leading medical facilities, including the Weatherhead PET center at the University of Texas Health Science Center in Houston, Texas; The Heart Center of Niagara in Niagara Falls, New York; Beth Israel Medical Center, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta, Georgia; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo, Japan. Additional information may be found at www.positron.com.

Forward Looking Statements:

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at [phone].